Spots Global Cancer Trial Database for donafenib
Every month we try and update this database with for donafenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma | NCT05161143 | Hepatocellular ... | Donafenib | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer | NCT02489201 | Oesophageal Can... | donafenib tosil... | 18 Years - | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | NCT05717738 | Hepatocellular ... | TACE Lenvatinib Anti-PD-1 monoc... Bevacizumab Bio... Bevacizumab plu... apatinib plus c... Sorafenib Donafenib Regorafenib | 18 Years - | Tongji Hospital | |
| Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | NCT04402723 | Acute Myeloid L... | Donafenib | 18 Years - 55 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC | NCT05493332 | Hepatocellular ... | HAIC(FOLFOX) Oxaliplatin Leucovorin Fluorouracil Toripalimab Donafenib | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen | NCT05138159 | Metastatic Panc... | Donafenib S1 | 18 Years - 75 Years | Fudan University | |
| GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma | NCT05668884 | Biliary Tract C... | Combination of ... | 18 Years - 75 Years | Fudan University | |
| Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma | NCT02229071 | HCC | Donafenib(200mg... Donafenib(300mg... | 18 Years - 70 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | NCT04402723 | Acute Myeloid L... | Donafenib | 18 Years - 55 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| HAIC Combined With Donafenib and Sintilimab for Unresectable ICC | NCT05348811 | Cholangiocarcin... | HAIC combined w... | 18 Years - 75 Years | Zhongda Hospital | |
| Donafenib for Previously Treated Metastatic Colorectal Cancer | NCT02870582 | Metastatic Colo... | Donafenib Placebo | 18 Years - 75 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma | NCT02698111 | Nasopharyngeal ... | Donafenib | 18 Years - | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery | NCT04962958 | Carcinoma Carcinoma, Hepa... Liver Neoplasms Digestive Syste... Antineoplastic ... Donafenib Fluorouracil Oxaliplatin Antimetabolites | Hepatic arteria... Folfox Protocol Donafenib | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma | NCT05166772 | Hepatocellular ... | Donafenib Sintilimab HAIC | 18 Years - 80 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma | NCT05161143 | Hepatocellular ... | Donafenib | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma | NCT02698111 | Nasopharyngeal ... | Donafenib | 18 Years - | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma | NCT05507632 | Unresectable He... | Donafenib plus ... | 18 Years - 75 Years | Nanfang Hospital, Southern Medical University | |
| Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | NCT05717738 | Hepatocellular ... | TACE Lenvatinib Anti-PD-1 monoc... Bevacizumab Bio... Bevacizumab plu... apatinib plus c... Sorafenib Donafenib Regorafenib | 18 Years - | Tongji Hospital | |
| HAIC Combined With Donafenib and Sintilimab for Unresectable ICC | NCT05348811 | Cholangiocarcin... | HAIC combined w... | 18 Years - 75 Years | Zhongda Hospital | |
| Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | NCT05713994 | Hepatocellular ... | HAIC Bevacizumab plu... Bevacizumab Bio... Lenvatinib Sorafenib Donafenib Regorafenib apatinib plus c... Anti-PD-1 monoc... | 18 Years - | Tongji Hospital | |
| A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC | NCT05205629 | Hepatocellular ... Donafenib | Donafenib combi... | 18 Years - | Shanghai Zhongshan Hospital | |
| Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | NCT05713994 | Hepatocellular ... | HAIC Bevacizumab plu... Bevacizumab Bio... Lenvatinib Sorafenib Donafenib Regorafenib apatinib plus c... Anti-PD-1 monoc... | 18 Years - | Tongji Hospital | |
| A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC | NCT05205629 | Hepatocellular ... Donafenib | Donafenib combi... | 18 Years - | Shanghai Zhongshan Hospital | |
| Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | NCT05717738 | Hepatocellular ... | TACE Lenvatinib Anti-PD-1 monoc... Bevacizumab Bio... Bevacizumab plu... apatinib plus c... Sorafenib Donafenib Regorafenib | 18 Years - | Tongji Hospital | |
| Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation | NCT05576909 | Hepatocellular ... | Donafenib TACE | 18 Years - 75 Years | Beijing Tsinghua Chang Gung Hospital | |
| HAIC Combined With Toripalimab and Donafenib for Advanced BTC | NCT05350943 | Biliary Tract A... | HAIC Gemcitabine Oxaliplatin Toripalimab Donafenib | 18 Years - 80 Years | Fudan University | |
| A Single Center Real-world Study of Donafenib in the Treatment of Hepatocellular Carcinoma in Routine Clinical Practice | NCT05200221 | Donafenib Hepatocellular ... | 18 Years - | Shanghai Zhongshan Hospital | ||
| A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC | NCT05205629 | Hepatocellular ... Donafenib | Donafenib combi... | 18 Years - | Shanghai Zhongshan Hospital | |
| HAIC Combined With Toripalimab and Donafenib for Advanced BTC | NCT05350943 | Biliary Tract A... | HAIC Gemcitabine Oxaliplatin Toripalimab Donafenib | 18 Years - 80 Years | Fudan University | |
| Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial. | NCT05171166 | Hepatocellular ... | HAIC TACE FOLFOX cTACE or DEB-TA... Donafenib | 18 Years - 75 Years | Peking University | |
| Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma | NCT02229071 | HCC | Donafenib(200mg... Donafenib(300mg... | 18 Years - 70 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen | NCT05138159 | Metastatic Panc... | Donafenib S1 | 18 Years - 75 Years | Fudan University | |
| Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma | NCT05166772 | Hepatocellular ... | Donafenib Sintilimab HAIC | 18 Years - 80 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Donafenib Plus Sintilimab for Advanced HCC | NCT05162352 | Hepatocellular ... | Donafenib+sinti... | 18 Years - | Second Affiliated Hospital of Guangzhou Medical University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
